Lancet:青光眼预防性激光治疗研究新进展

2019-03-30 佚名 中山眼科中心

青光眼是首位不可逆性致盲眼病,最常见的类型包括:原发性开角型青光眼和原发性闭角型青光眼。目前,我国有2800万闭角型青光眼的高危患者。按照医疗常规,这部分高危患者需要进行预防性激光手术。中山大学中山眼科中心何明光教授团队通过持续六年的研究,发现这些高危患者转变为青光眼的比例很低,因此不建议在高危患者换这种中广泛使用这种预防性激光治疗。

青光眼是首位不可逆性致盲眼病,最常见的类型包括:原发性开角型青光眼和原发性闭角型青光眼。目前,我国有2800万闭角型青光眼的高危患者。按照医疗常规,这部分高危患者需要进行预防性激光手术。中山大学中山眼科中心何明光教授团队通过持续六年的研究,发现这些高危患者转变为青光眼的比例很低,因此不建议在高危患者换这种中广泛使用这种预防性激光治疗。

3月13日,这项成果以题为《激光虹膜周切术预防房角关闭:一项单中心随机对照临床试验》的论文在国际顶级医学期刊《柳叶刀》在线发表。

该研究是为期6年的单中心临床随机对照试验。何教授团队对广州市荔湾区50-70岁人群进行社区筛查,最终从11991名筛查对象中入选了889名临床试验受试者。所有受试者均达到预定的双眼可疑原发性房角关闭入选标准。对受试者双眼进行随机分组,其中一眼分配至激光虹膜周边切开,作为干预组,对侧眼不进行治疗,作为对照。进行激光治疗后,对受试者进行定期随访至72个月。眼压升高、发生前房角粘连或急性青光眼发作作为主要结局指标。研究发现在干预组,每1000眼×年中,主要结局指标发生率为4.19,而对照眼为7.97;风险比为0.53。其中,干预组出现19例主要结局指标,对照组出现36例主要结局指标;两组间具有统计学显着差异。

虽然临床试验证实预防性激光治疗可以降低47%的主要结局指标的发生,但是由于主要结局指标本身的发生率极低,而且都以不会马上引起视力损伤的前房角粘连为主,因此,对于通过社区筛查找到的闭角型青光眼“高危患者”,研究结果提示,不应广泛使用预防性激光治疗。这个临床实践的改变,可能会减少没有必要的手术治疗,降低卫生资源的投入。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830001, encodeId=b50218300013b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu May 23 19:52:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034805, encodeId=71d9203480501, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Apr 27 08:52:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033292, encodeId=2762203329258, content=<a href='/topic/show?id=692328816d7' target=_blank style='color:#2F92EE;'>#光治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28816, encryptionId=692328816d7, topicName=光治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Sun Jun 09 19:52:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279741, encodeId=0a8012e97416d, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Apr 01 08:52:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434723, encodeId=bd621434e23db, content=<a href='/topic/show?id=817f66e686a' target=_blank style='color:#2F92EE;'>#激光治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66768, encryptionId=817f66e686a, topicName=激光治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Apr 01 08:52:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
    2019-05-23 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830001, encodeId=b50218300013b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu May 23 19:52:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034805, encodeId=71d9203480501, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Apr 27 08:52:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033292, encodeId=2762203329258, content=<a href='/topic/show?id=692328816d7' target=_blank style='color:#2F92EE;'>#光治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28816, encryptionId=692328816d7, topicName=光治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Sun Jun 09 19:52:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279741, encodeId=0a8012e97416d, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Apr 01 08:52:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434723, encodeId=bd621434e23db, content=<a href='/topic/show?id=817f66e686a' target=_blank style='color:#2F92EE;'>#激光治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66768, encryptionId=817f66e686a, topicName=激光治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Apr 01 08:52:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830001, encodeId=b50218300013b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu May 23 19:52:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034805, encodeId=71d9203480501, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Apr 27 08:52:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033292, encodeId=2762203329258, content=<a href='/topic/show?id=692328816d7' target=_blank style='color:#2F92EE;'>#光治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28816, encryptionId=692328816d7, topicName=光治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Sun Jun 09 19:52:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279741, encodeId=0a8012e97416d, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Apr 01 08:52:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434723, encodeId=bd621434e23db, content=<a href='/topic/show?id=817f66e686a' target=_blank style='color:#2F92EE;'>#激光治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66768, encryptionId=817f66e686a, topicName=激光治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Apr 01 08:52:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
    2019-06-09 hyf028
  4. [GetPortalCommentsPageByObjectIdResponse(id=1830001, encodeId=b50218300013b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu May 23 19:52:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034805, encodeId=71d9203480501, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Apr 27 08:52:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033292, encodeId=2762203329258, content=<a href='/topic/show?id=692328816d7' target=_blank style='color:#2F92EE;'>#光治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28816, encryptionId=692328816d7, topicName=光治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Sun Jun 09 19:52:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279741, encodeId=0a8012e97416d, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Apr 01 08:52:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434723, encodeId=bd621434e23db, content=<a href='/topic/show?id=817f66e686a' target=_blank style='color:#2F92EE;'>#激光治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66768, encryptionId=817f66e686a, topicName=激光治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Apr 01 08:52:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
    2019-04-01 oliver169
  5. [GetPortalCommentsPageByObjectIdResponse(id=1830001, encodeId=b50218300013b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu May 23 19:52:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034805, encodeId=71d9203480501, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Apr 27 08:52:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033292, encodeId=2762203329258, content=<a href='/topic/show?id=692328816d7' target=_blank style='color:#2F92EE;'>#光治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28816, encryptionId=692328816d7, topicName=光治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Sun Jun 09 19:52:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279741, encodeId=0a8012e97416d, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Apr 01 08:52:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434723, encodeId=bd621434e23db, content=<a href='/topic/show?id=817f66e686a' target=_blank style='color:#2F92EE;'>#激光治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66768, encryptionId=817f66e686a, topicName=激光治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Apr 01 08:52:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]

相关资讯

J Glaucoma:快速青光眼进展患者的生活质量和视力相关的表现研究

宾夕法尼亚州费城威尔斯眼科医院青光眼研究中心的Waisbourd M等人在J Glaucoma杂志上发表了一篇文章,他们对青光眼发展迅速的临床测量参数是如何影响患者的进行了研究。临床测量主要是基于行为表现的测量和视力相关生活质量(VRQoL)的主观评价。

J Glaucoma:视神经乳头倾斜对近视正常眼压青光眼视野缺损的影响

韩国三星医疗中心眼科的Choi JH等人近日在J Glaucoma杂志上发表了一篇重要的研究论文,他们研究了视神经乳头(ONH)倾斜是否与近视、正常眼压性青光眼(NTG)中的视野(VF)缺陷有关。

Mannin Research与麦克马斯特大学合作眼部靶向输送候选药物MAN-01:治疗青光眼

Q BioMed是一家生物技术公司,今天宣布其技术合作伙伴Mannin Research已与加拿大麦克马斯特大学合作MAN-01的眼部药物输送。MAN-01是治疗原发性开角型青光眼的一线小分子化合物。

Lancet:选择性激光小梁成形术治疗开角型青光眼和高眼压

研究认为因采用选择性激光小梁成形术应作为治疗开角型青光眼和高眼压的一线手段

Jpn J Ophthalmol:椎间盘出血对青光眼的影响

日本岐阜大学医学研究科眼科的Yamamoto T在Jpn J Ophthalmol杂志上发表了一篇重要的综述文章,从椎间盘出血研究方面讨论了临床对青光眼发生的理解。

Netarsudil眼科解决方案在II期临床中取得积极成果

Aerie是一家眼科制药公司,专注于开发和商业化一流的眼科疗法,用于治疗患有青光眼、视网膜疾病和其他眼科疾病的患者。Aerie近日宣布了其在日裔美国人群中对Netarsudil眼用溶液进行的第II阶段试验研究的最终结果。